Author: Vanessa Ngan, Staff Writer, 2006. Updated by Dr Jannet Gomez, December 2016.
Epidermodysplasia verruciformis (EV) is a rare, autosomal recessive inherited skin disorder characterised by a chronic eruption of brownish plaques.
A similar disorder, known as acquired epidermodysplasia verruciformis, may arise in patients with impaired immunity
Each epidermodysplasia verruciformis patch is caused by an infection with a subtype of human papillomavirus (HPV).
HPV has numerous subtypes, which cause a wide range of viral warts. Some subtypes of HPV have minimal or no clinical effect in most people yet the same subtypes result in the clinical features of epidermodysplasia verruciformis in people with an impaired immune response to the virus. More than 30 subtypes of HPV have been implicated.
Epidermodysplasia verruciformis is usually an autosomal recessive inherited disorder, which means that the individual has gained an abnormal EV gene from each parent. The parents of about 10% of patients with epidermodysplasia verruciformis are blood relatives (ie, the parents share a common ancestor). In a few cases, sex-linked and autosomal dominant inheritance patterns have also been reported.
Epidermodysplasia verruciformis is often due to mutations in the EVER1 or EVER2 genes on chromosome 17q25. The mutation decreases cell capacity to fight HPV infections. In cases that lack this mutation, mutations in RAS homolog gene family member H (RHOH), MST1 deficiency, and splicing deficiency in the gene encoding LCK (lymphocyte specific kinase) have been found.
The lesions usually start to appear during childhood and persist. About 7.5% of cases appear in infancy, 61.5% in children aged 5–11 years and 22.5% in puberty. The disease affects both males and females and people of all races.
Acquired epidermodysplasia verruciformis is a result of HIV infection, organ transplantation or a lymphoma.
Two clinical presentations have been described in epidermodysplasia verruciformis.
Warts occur in irregular clusters of a few to over a hundred lesions. They are especially prevalent in sun-exposed areas such as the hands, feet, face, and earlobes. Plaque-like lesions usually appear on the trunk, neck, arms and legs. The palms, soles, armpits and external genitals may also be involved.
A major concern for patients with epidermodysplasia verruciformis is that in 30-60% of EV patients the lesions may transform into skin cancers; these are mostly cutaneous squamous cell carcinoma and intraepidermal squamous cell carcinoma. Basal cell carcinoma and adnexal tumours are less common. Malignant tumours are usually found in patients 30–50 years of age.
Over 90% of EV-associated skin cancers contain HPV types 5, 8, 10, and 47. EV lesions caused by HPV 14, 20, 21, and 25 usually remain benign. Exposure to sunlight or ultraviolet radiation increases the chance that a benign wart will develop into skin cancer.
Diagnosis is usually clinical. Epidermodysplasia verruciformis is suspected when there are a large number of treatment-resistant viral warts. A skin biopsy may reveal characteristic features (see epidermodysplasia verruciformis pathology).
Some laboratories can report the subtype of HPV by polymerase chain reaction (PCR).
Epidermodysplasia verruciformis is a lifelong disease. Even though lesions can be treated or removed as they appear, the lesions develop throughout life.
Currently there is no treatment to prevent new lesions from occurring. The management of EV involves a combination of medical and surgical treatments alongside patient counselling, education and regular surveillance (especially if immunocompromised).
See the DermNet NZ bookstore
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.